ZyVersa (ZVSA): רווח נקי למניה (EPS TTM)

ZyVersa Therapeutics (ZVSA) is building a foundation of reliability by focusing on therapies for nephrological pathologies with immense market potential. Fundamental TTM net income per share clearly confirms the current development trajectory. Patent protection for unique inhibitors guarantees a future monopoly, and the value of -4.66 characterizes this level. The absence of current sales is offset by high future margins for the drugs following the completion of clinical trials.
פילוחים אנליטיים ודוחות נתונים של חברת zyversa.com (ZVSA)

ZyVersa Therapeutics (ZVSA) creates value through proprietary inflammasome inhibitors to combat renal failure. The TTM EPS is calculated as the ratio of annual net income to the average number of shares, reflecting the actual return on a single share of capital. Investors utilize this metric to separate the fundamental value of the business from market noise. Profit dynamics allow for an assessment of the effectiveness of biotechnology commercialization. By analyzing the TTM EPS history, one can determine the degree of the asset's undervaluation.